StockNews.com started coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a report issued on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald boosted their price target on shares of MannKind from $6.50 to $7.50 and […]
MannKind (NASDAQ:MNKD) PT Raised to $7 50 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
MannKind (NASDAQ:MNKD – Get Free Report) had its price target upped by investment analysts at Cantor Fitzgerald from $6.50 to $7.50 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 41.78% from […]
MannKind (NASDAQ:MNKD – Get Free Report) had its target price upped by equities research analysts at Cantor Fitzgerald from $6.50 to $7.50 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 41.78% from […]